FORM 4			OMB APPROVAL			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. (Print or Type Responses)	Filed pursuant to	UNITED STATES SECURITIES AND EXCHANGE COMMISSIO Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECU Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Inves	OMB Number: 3235-0287 Estimated average burden hours per response 0.5			
1. Name and Address of Reporting Person * Kalif Eliyahu Sharon		2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited [TEVA]	5. Relationship of Reporting Pe (C. Director	orting Person(s) to Issuer (Check all applicable) 10% Owner		
(Last) (First) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St.,	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 06/12/2025	ow) Other (specify below) , Chief Financial Officer			
(Street)		4. If Amendment, Date Original Filed (Month/Day/Year)	ing (Check Applicable Line)			

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Tel Aviv, L3 6944020

(City)

(State)

(Zip)

1.Title of Security (Instr. 3)	2. Transaction Date (Month /Day/Year)	2A. Deemed Execution Date, if any (Month/Day /Year)	Code		Disposed of (D)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Beneficial
			Code	V	Amount	(A) or (D)	Price		()	Ownership (Instr. 4)
Ordinary Shares ⁽¹⁾	06/12/2025		S ⁽²⁾		55,775	D	\$ 17.0769 ⁽³⁾	403,288	D	

_____ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (*e.g.*, puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)		Execution	4. Transact Code (Instr. 8)		5. Number of Derivative Securiti Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Date		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		(Instr. 5)	of Derivative Securities Beneficially	Form of Derivative Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		1	Direct (D) or Indirect (I) (Instr. 4)	

Explanation of Responses:

- 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- 2. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2024.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$17.055 to \$17.12, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

/s/ Dov Bergwerk as attorney-in-fact for Eliyahu Sharon Kalif 06/16/2025

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.